Plus Therapeutics announced on June 30, 2025, the initiation of the ReSPECT-LM dose optimization trial for REYOBIQ™ for the treatment of leptomeningeal metastases (LM). This trial follows encouraging results from the company’s single-dose escalation trial.
The study design is consistent with the FDA’s Project Optimus, aiming to optimize treatment dosing for maximum efficacy and safety. Primary objectives include determining the safety, tolerability, maximum tolerated dose, and minimum effective dose of multiple REYOBIQ doses.
The ReSPECT-LM dose optimization trial benefits from a $17.6 million grant from the Cancer Prevention & Research Institute of Texas (CPRIT). The trial will initially be conducted at two prestigious cancer centers in Texas: the University of Texas Health Science Center at San Antonio and the University of Texas Southwestern Medical Center.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.